Claris Financial LLC Makes New Investment in Eli Lilly and Company $LLY

Claris Financial LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 937 shares of the company’s stock, valued at approximately $1,007,000.

Several other large investors also recently bought and sold shares of LLY. TMB Capital Partners LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $456,000. Briggs Wealth Management Inc purchased a new position in Eli Lilly and Company during the 4th quarter worth approximately $305,000. Evansbrook LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth approximately $1,461,000. Harbour Wealth Management Group Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth approximately $487,000. Finally, Lexington Hill Partners LLC purchased a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $448,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Several articles highlighted Eli Lilly’s strong growth profile and ongoing investor support, including coverage that Ray Dalio’s Bridgewater sees LLY as a top growth name and that some analysts view the stock as undervalued on its growth narrative. Eli Lilly and Company (LLY) is one of the Best Growth Stocks to Buy According Ray Dalio
• Positive Sentiment: Lilly’s pipeline news was broadly constructive, including completion of a retatrutide trial and early signs from its AJX-101 study, which suggest continued momentum in diabetes, obesity, and immunology programs. Eli Lilly and Company (LLY) is one of the Best Growth Stocks to Buy According Ray Dalio
• Positive Sentiment: The company also expanded its AI drug-discovery ecosystem, with Charles River, Chai Discovery, and Axcelead DDP joining Lilly TuneLab, supporting longer-term innovation and partnership potential. Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs
• Neutral Sentiment: Recent articles also noted Lilly remains a major leader in obesity treatment, with investor debate around whether newer competitors like Pfizer can take share; this underscores the size of the opportunity but also the competitive backdrop. Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?
• Negative Sentiment: One of the bigger drags on sentiment was Lilly’s decision to halve a planned €2.7 billion Germany investment, citing European drug-pricing reforms that could pressure future R&D and manufacturing commitments. Eli Lilly (LLY) Halves $2.7 Billion Germany Investment Over Europe Drug Pricing
• Negative Sentiment: Another potential overhang is Lilly beginning to deny some 340B discounts, which could increase policy and pricing friction with healthcare providers and public programs. Eli Lilly begins denying 340B discounts

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,098.78 on Friday. The firm’s fifty day simple moving average is $1,013.17 and its 200-day simple moving average is $1,016.84. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The stock has a market cap of $1.03 trillion, a PE ratio of 39.03, a price-to-earnings-growth ratio of 1.22 and a beta of 0.53. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,182.73.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were paid a $1.73 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Guggenheim reiterated a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 target price on shares of Eli Lilly and Company in a report on Friday, March 6th. HSBC downgraded shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their target price for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Finally, Barclays raised their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,227.74.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.